A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation

SIMPLE SUMMARY: Tyrosine kinase inhibitors (TKIs) targeting anaplastic lymphoma kinase (ALK), such as crizotinib and alectinib, provide favorable clinical responses in human malignancies driven by ALK fusion proteins, including ALK-positive anaplastic large cell lymphoma (ALK(+) ALCL) and non-small...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawasoe, Kazunori, Watanabe, Tatsuro, Yoshida-Sakai, Nao, Yamamoto, Yuta, Kurahashi, Yuki, Kidoguchi, Keisuke, Ureshino, Hiroshi, Kamachi, Kazuharu, Fukuda-Kurahashi, Yuki, Kimura, Shinya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605931/
https://www.ncbi.nlm.nih.gov/pubmed/37894456
http://dx.doi.org/10.3390/cancers15205089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605931/
https://www.ncbi.nlm.nih.gov/pubmed/37894456
http://dx.doi.org/10.3390/cancers15205089

Ejemplares similares